# Lenz Therapeutics, Inc.

**LENZ**

Nasdaq; healthcare; SIC 2836, Biological Products, (No Diagnostic Substances); CIK 0001815776

**D**

**fourth fifth of 370 graded peers in healthcare**

rank 234 of 370; percentile 63.1; sampling error 2.5 points; lower is stronger

A B C D E

**D, the sloth**



## Scoreboard

| | |
|---|---|
| **Profitability** | D<br>percentile 71.3 |
| **Solvency** | B<br>percentile 30.7 |
| **Growth and financing** | C<br>percentile 55.4 |
| **Reliability** | 0.87 AUC<br>filers with $120M to $591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025 |
| **Peer failure rate** | 1.03% a year<br>Item 1.03 bankruptcies, same asset band, 2012 to 2025 |
| **Size band** | $120M to $591M assets<br>total assets $305.9M |
| **Standard universe** | inside<br>revenue above $1M and assets above $10M |
| **Warnings** | short runway<br>not computable: fortress balance sheet |
| **Inputs computable** | 7 of 14 |
| **Graded from** | filings received through Mar 24, 2026<br>209 days before the rescan; latest periodic filing 10-Q received Aug 11, 2026 |
| **Last close** | $3.27<br>2026-10-16; market equity $102.9M; no price enters the letter |

**Share price, twelve months to the rescan**




*Split-adjusted close. Each lollipop is a rescan and carries the letter held then.*

**Letter at every rescan, 2012 to 2026**




*Sector percentile at each rescan, stronger toward the top; facts filed by each date only.*

## Business, in the company's words

*opening of Item 1 of the 10-K received Mar 24, 2026*

We are a commercial pharmaceutical company focused on the development and commercialization of innovative therapies to improve vision. On July 31, 2025, the United States ("U.S.") Food and Drug Administration ("FDA") approved VIZZ® (aceclidine ophthalmic solution) 1.44%, formerly known as LNZ100, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the U.S. We are commercializing VIZZ in the U.S. and continue to establish licensing and distribution partnerships internationally to provide access to VIZZ globally.

## The fourteen inputs

*lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight*

| Input | Value | Peer median | Percentile, 0 to 100 | Pct | Peers | Period end |
|---|---|---|---|---|---|---|
| **Profitability, sleeve percentile 71.3** | | | | | | |
| Gross profitability | 6.1% | 32.3% | | 81.4 | 371 | 2025-12-31 |
| Return on invested capital | not computable | 9.3% | | | | |
| *one or more required annual facts are missing* | | | | | | |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | |
|---|---|---|---|---|---|
| Accruals ratio | (5.0%) | (6.6%) | 61.3 | 812 | 2025-12-31 |
| Gross margin stability, five years | not computable | 2.8 pts | | | |
| *five annual gross margins are required; found 1* | | | | | |
| **Solvency, sleeve percentile 30.7** | | | | | |
| Twelve-month failure probability | 0.35% | 0.07% | 79.3 | 247 | 2026-06-30 |
| Altman Z double-prime | 15.45 | (0.30) | 4.4 | 757 | 2025-12-31 |
| Net debt to EBITDA | not computable | 1.82x | | | |
| *one or more required annual facts are missing* | | | | | |
| Interest coverage | not computable | (4.51x) | | | |
| *one or more required annual facts are missing* | | | | | |
| Current ratio | 14.23x | 2.96x | 8.3 | 840 | 2025-12-31 |
| **Growth and financing, sleeve percentile 55.4** | | | | | |
| Revenue growth, three-year compound | not computable | 10.1% | | | |
| *four annual observations are required; found 1* | | | | | |
| Free cash flow growth, three-year compound | not computable | 10.9% | | | |
| *current FCF must be positive and base FCF must exceed $100,000* | | | | | |
| Reinvestment rate | not computable | 37.1% | | | |
| *pretax income must exceed the validity floor and imply a 0%-100% tax rate* | | | | | |
| Asset growth, three years | (1.7%) | 2.1% | 55.1 | 705 | 2025-12-31 |
| Net share issuance, one year | 13.8% | 2.5% | 55.6 | 634 | 2026-03-18 |

## Warnings

*1 of 7 checks triggered; none of them enters the letter*

| Check | Measured |
|---|---|
| Short runway | cash runway is 2.6 months |

## Among 370 peers

*healthcare; letters are fifths of this list*




*Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.*

| Rank | Company | Percentile | Letter | Warnings |
|---|---|---|---|---|
| 229 | Akebia Therapeutics, Inc. (AKBA) | 61.8 | C/D | fortress balance sheet |
| 230 | Strata Critical Medical, Inc. (SRTA) | 62.1 | C/D | short runway, fortress balance sheet |
| 231 | Embecta Corp. (EMBC) | 62.3 | C/D | late filer |
| 232 | Mannkind Corp. (MNKD) | 62.6 | D | |
| 233 | Biogen Inc. (BIIB) | 62.9 | D | |
| 234 | Lenz Therapeutics, Inc. (LENZ) | 63.1 | D | short runway |
| 235 | AbbVie Inc. (ABBV) | 63.4 | D | |
| 236 | Caribou Biosciences, Inc. (CRBU) | 63.7 | D | short runway |
| 237 | Royalty Pharma plc (RPRX) | 64.0 | D | |
| 238 | Integra Lifesciences Holdings Corp. (IART) | 64.2 | D | |
| 239 | Arvinas, Inc. (ARVN) | 64.5 | D | short runway, fortress balance sheet |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

## What the price implies

*at the 2026-10-16 close; none of these enters the grade*

| Measure | Value | Peer median | Percentile |
|---|---|---|---|
| Twelve-month price change, skipping the latest month | (88.8%) | 8.0% | 2 |
| Distance from 52-week high | (91.9%) | (33.0%) | 4 |
| EBIT to enterprise value | not computable | (1.7%) | |
| Free cash flow yield | (68.1%) | (1.0%) | 9 |
| Book value to price | 2.13 | 0.28 | 96 |
| Sales to price | 0.19 | 0.31 | 38 |
| Composite equity issuance, five years | not computable | 20.3% | |
| Relative strength against the sector, log excess return | (2.40) | (0.13) | 2 |

## Diagnostics

*shown on every report; none enters the grade*

| Measure | Value |
|---|---|
| **Piotroski F-score None of 9, period end 2025-12-31** | |
| Return on assets above zero | fail |
| Operating cash flow above zero | fail |
| Return on assets improved | pass |
| Operating cash flow exceeds net income | pass |
| Long-term leverage fell | fail |
| Current ratio improved | fail |
| No new shares issued | fail |
| Gross margin improved | fail |
| Asset turnover improved | fail |
| **Cash, filings, liquidity** | |
| Cash and equivalents | $24.2M |
| Operating cash flow, four quarters | -$113.9M |
| Months of runway | 2.6 |
| Days since last periodic filing | 69 (10-Q received Aug 11, 2026) |
| Median daily dollar volume, 63 sessions | $3.2M |

## Sources

*every fact behind the inputs; each row links to its filing index on sec.gov*

| # | Concept | XBRL tag | Value | Period end | Received | Form | Accession |
|---|---|---|---|---|---|---|---|
| 1 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $19.1M | 2025-12-31 | 2026-03-24 | 10-K | 26-000011 |
| 2 | cost of revenue | us-gaap:CostOfGoodsAndServicesSold | $418,000 | 2025-12-31 | 2026-03-24 | 10-K | 26-000011 |
| 3 | assets | us-gaap:Assets | $305.9M | 2025-12-31 | 2026-03-24 | 10-K | 26-000011 |
| 4 | net income | us-gaap:NetIncomeLoss | -$82.1M | 2025-12-31 | 2026-03-24 | 10-K | 26-000011 |
| 5 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$69.2M | 2025-12-31 | 2026-03-24 | 10-K | 26-000011 |
| 6 | assets | us-gaap:Assets | $215.3M | 2024-12-31 | 2026-03-24 | 10-K | 26-000011 |
| 7 | current assets | us-gaap:AssetsCurrent | $301.4M | 2025-12-31 | 2026-03-24 | 10-K | 26-000011 |
| 8 | current liabilities | us-gaap:LiabilitiesCurrent | $21.2M | 2025-12-31 | 2026-03-24 | 10-K | 26-000011 |
| 9 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | -$227.1M | 2025-12-31 | 2026-03-24 | 10-K | 26-000011 |
| 10 | operating income | us-gaap:OperatingIncomeLoss | -$91.1M | 2025-12-31 | 2026-03-24 | 10-K | 26-000011 |
| 11 | book equity | us-gaap:StockholdersEquity | $284.3M | 2025-12-31 | 2026-03-24 | 10-K | 26-000011 |
| 12 | liabilities | us-gaap:Liabilities | $21.5M | 2025-12-31 | 2026-03-24 | 10-K | 26-000011 |
| 13 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $827,000 | 2025-12-31 | 2026-03-24 | 10-K | 26-000011 |
| 14 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$59.4M | 2024-12-31 | 2026-03-24 | 10-K | 26-000011 |
| 15 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $468,000 | 2024-12-31 | 2026-03-24 | 10-K | 26-000011 |
| 16 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$60.4M | 2023-12-31 | 2025-03-19 | 10-K | 25-000019 |
| 17 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $30,000 | 2023-12-31 | 2025-03-19 | 10-K | 25-000019 |
| 18 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$88.0M | 2022-12-31 | 2024-02-27 | 10-K | 24-021135 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| 19 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $6.6M | 2022-12-31 | 2024-02-27 | 10-K | 24-021135 |
| 20 | depreciation amortization | us-gaap:DepreciationDepletionAndAmortization | $287,000 | 2025-12-31 | 2026-03-24 | 10-K | 26-000011 |
| 21 | pretax income | us-gaap:IncomeLossFromContinuingOperationsBeforeInc... | -$81.6M | 2025-12-31 | 2026-03-24 | 10-K | 26-000011 |
| 22 | income tax | us-gaap:IncomeTaxExpenseBenefit | $502,000 | 2025-12-31 | 2026-03-24 | 10-K | 26-000011 |
| 23 | current assets | us-gaap:AssetsCurrent | $211.9M | 2024-12-31 | 2026-03-24 | 10-K | 26-000011 |
| 24 | current liabilities | us-gaap:LiabilitiesCurrent | $10.4M | 2024-12-31 | 2026-03-24 | 10-K | 26-000011 |
| 25 | assets | us-gaap:Assets | $70.4M | 2023-12-31 | 2025-03-19 | 10-K | 25-000019 |
| 26 | assets | us-gaap:Assets | $321.9M | 2022-12-31 | 2024-02-27 | 10-K | 24-021135 |
| 27 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 31,354,394 | 2026-03-18 | 2026-03-24 | 10-K | 26-000011 |
| 28 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 27,542,874 | 2025-03-12 | 2025-03-19 | 10-K | 25-000019 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.